
How can we make advanced metabolomics accessible for routine clinical use — at an affordable cost — in service of the greater good of prevention and personalized medicine?
Earlier this year at Arab Health in Dubai, Ali Tinazli spoke about our work at Lifespin GmbH and how our General Health Assessment (GHA) supports that goal. This short interview highlights: • Why